January 6, 2021
“9 Meters Biopharma (NMTR)… Turning now to the rest of the Street, other analysts are on the same page. With 4 Buys and no Holds or Sells, the word on the Street is that NMTR is a Strong Buy. Given… Continue Reading…
January 4, 2021
“ElectraMeccanica Vehicles (SOLO)… Speculative tech is popular on Wall Street, and ElectraMeccanica fits that bill nicely. The company has 3 recent reviews, and all are Buys, making the analyst consensus a unanimous Strong Buy. Shares are priced at $6.19 and… Continue Reading…
December 18, 2020
“UMH Properties (UMH)… Overall, the unanimous Strong Buy on UMH is based on 5 recent reviews. The stock is selling for $15.92, and the $18.40 average price target suggests it has room for 15% growth from that level… Laird Superfood (LSF)… Laird… Continue Reading…
December 17, 2020
“UMH Properties (UMH)… Overall, the unanimous Strong Buy on UMH is based on 5 recent reviews. The stock is selling for $15.92, and the $18.40 average price target suggests it has room for 15% growth from that level… Laird Superfood (LSF)… Burleson… Continue Reading…
December 10, 2020
“Turning Point Brands (TPB)… Overall, the Strong Buy consensus rating on Turning Points Brands is unanimous, standing on 5 Buy-side reviews. The stock is selling for $42.60, and its $46.46 average price target implies ~9% upside from current levels… Gladstone Lands… Continue Reading…
December 8, 2020
“Baxter International (BAX)… Overall, the analyst consensus rating on Baxter is a Strong Buy, based on 12 reviews that include 11 Buys against just a single Hold. The stock is selling for $78, and its $95 average price target suggest it… Continue Reading…
December 3, 2020
“Nomad Foods (NOMD)… Overall, Nomad has 6 recent reviews, breaking down in a 5-to-1 split of Buy versus Hold. This makes the analyst consensus view a Strong Buy. The average price target is $28.33, for a 19% one-year upside from… Continue Reading…
December 2, 2020
“Cellectar Biosciences (CLRB)… Are other analysts in agreement? They are. 5 Buys and no Holds or Sells have been issued in the last three months. So, the message is clear: CLRB is a Strong Buy. Given the $5.48 average price… Continue Reading…
November 30, 2020
“G1 Therapeutics (GTHX)… Are other analysts in agreement? They are. Only Buy ratings, 3 to be exact, have been issued in the last three months. Therefore, the message is clear: GTHX is a Strong Buy. Given the $59 average price… Continue Reading…
Recent Comments